T-cell engaging bsAbs targeting prostate-specific membrane antigen (PSMA) 136, delta-like protein 3 (DLL3) 137, and HER2 138 are showing promise in preclinical and early clinical trials for PCa, as is a trispecific PSMA-targeting T-cell engager that is derived from the half-life extended TriTAC platform 139. This evidence concerns the gene FOLH1 and posterior cortical atrophy.